These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 9209292)
1. Substrates and inhibitors of human T-cell leukemia virus type 1 (HTLV-1) proteinase. Hrusková-Heidingsfeldová O; Bláha I; Urban J; Strop P; Pichová I Leukemia; 1997 Apr; 11 Suppl 3():45-6. PubMed ID: 9209292 [TBL] [Abstract][Full Text] [Related]
2. Substrates and inhibitors of human T-cell leukemia virus type I protease. Ding YS; Rich DH; Ikeda RA Biochemistry; 1998 Dec; 37(50):17514-8. PubMed ID: 9860866 [TBL] [Abstract][Full Text] [Related]
3. Stabilization from autoproteolysis and kinetic characterization of the human T-cell leukemia virus type 1 proteinase. Louis JM; Oroszlan S; Tözsér J J Biol Chem; 1999 Mar; 274(10):6660-6. PubMed ID: 10037763 [TBL] [Abstract][Full Text] [Related]
4. Solid phase synthesis of the proteinase of bovine leukemia virus. Comparison of its specificity to that of HIV-2 proteinase. Bláha I; Tözsér J; Kim Y; Copeland TD; Oroszlan S FEBS Lett; 1992 Sep; 309(3):389-93. PubMed ID: 1325379 [TBL] [Abstract][Full Text] [Related]
5. Narrow substrate specificity and sensitivity toward ligand-binding site mutations of human T-cell Leukemia virus type 1 protease. Kádas J; Weber IT; Bagossi P; Miklóssy G; Boross P; Oroszlan S; Tözsér J J Biol Chem; 2004 Jun; 279(26):27148-57. PubMed ID: 15102858 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of activity of the protease from bovine leukemia virus. Ménard A; Leonard R; Llido S; Geoffre S; Picard P; Berteau F; Precigoux G; Hospital M; Guillemain B FEBS Lett; 1994 Jun; 346(2-3):268-72. PubMed ID: 8013645 [TBL] [Abstract][Full Text] [Related]
7. Analysis of substrate cleavage by recombinant protease of human T cell leukaemia virus type 1 reveals preferences and specificity of binding. Daenke S; Schramm HJ; Bangham CR J Gen Virol; 1994 Sep; 75 ( Pt 9)():2233-9. PubMed ID: 8077922 [TBL] [Abstract][Full Text] [Related]
8. Comparison of the substrate specificity of the human T-cell leukemia virus and human immunodeficiency virus proteinases. Tözsér J; Zahuczky G; Bagossi P; Louis JM; Copeland TD; Oroszlan S; Harrison RW; Weber IT Eur J Biochem; 2000 Oct; 267(20):6287-95. PubMed ID: 11012683 [TBL] [Abstract][Full Text] [Related]
9. Bovine leukemia virus protease: comparison with human T-lymphotropic virus and human immunodeficiency virus proteases. Sperka T; Miklóssy G; Tie Y; Bagossi P; Zahuczky G; Boross P; Matúz K; Harrison RW; Weber IT; Tözsér J J Gen Virol; 2007 Jul; 88(Pt 7):2052-2063. PubMed ID: 17554040 [TBL] [Abstract][Full Text] [Related]
10. Kinetic characterization of newly discovered inhibitors of various constructs of human T-cell leukemia virus-1 (HTLV-1) protease and their effect on HTLV-1-infected cells. Demir A; Oguariri RM; Magis A; Ostrov DA; Imamichi T; Dunn BM Antivir Ther; 2012; 17(5):883-92. PubMed ID: 22436331 [TBL] [Abstract][Full Text] [Related]
11. 15gag proteinase of myeloblastosis-associated virus: specificity studies with substrate-based inhibitors. Pavlícková L; Stys D; Soucek M; Urban J; Hrusková O; Sedlácek J; Strop P Arch Biochem Biophys; 1992 Nov; 298(2):753-6. PubMed ID: 1417001 [TBL] [Abstract][Full Text] [Related]
12. Human T-cell leukemia virus type 1 protease protein expressed in Escherichia coli possesses aspartic proteinase activity. Saiga A; Tanaka T; Orita S; Sato A; Sato S; Hachisu T; Abe K; Kimura Y; Kondo Y; Fujiwara T Arch Virol; 1993; 128(3-4):195-210. PubMed ID: 8435041 [TBL] [Abstract][Full Text] [Related]
13. Development of [Ile⁴⁰]HTLV-I protease inhibition assay using novel fluorogenic and chromogenic substrate. Kumada HO; Nguyen JT; Kakizawa T; Hidaka K; Kimura T; Hayashi Y; Kiso Y J Pept Sci; 2011 Aug; 17(8):569-75. PubMed ID: 21574213 [TBL] [Abstract][Full Text] [Related]
14. Truncation and non-natural amino acid substitution studies on HTLV-I protease hexapeptidic inhibitors. Nguyen JT; Zhang M; Kumada HO; Itami A; Nishiyama K; Kimura T; Cheng M; Hayashi Y; Kiso Y Bioorg Med Chem Lett; 2008 Jan; 18(1):366-70. PubMed ID: 18006315 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and activity of tetrapeptidic HTLV-I protease inhibitors possessing different P3-cap moieties. Zhang M; Nguyen JT; Kumada HO; Kimura T; Cheng M; Hayashi Y; Kiso Y Bioorg Med Chem; 2008 May; 16(10):5795-802. PubMed ID: 18400502 [TBL] [Abstract][Full Text] [Related]
16. Privileged Structures Meet Human T-Cell Leukemia Virus-1 (HTLV-1): C2-Symmetric 3,4-Disubstituted Pyrrolidines as Nonpeptidic HTLV-1 Protease Inhibitors. Kuhnert M; Blum A; Steuber H; Diederich WE J Med Chem; 2015 Jun; 58(11):4845-50. PubMed ID: 26000468 [TBL] [Abstract][Full Text] [Related]